Skip to content

Validation of Next Generation Cerebral and Tissue Oximeter

Validation of Next Generation INVOS NIRS Cerebral and Tissue Oximeter to Measure Cerebral and Somatic Tissue Oxygen Saturation in Healthy Volunteers

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03128372
Enrollment
32
Registered
2017-04-25
Start date
2017-05-22
Completion date
2017-07-19
Last updated
2018-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxygen Deficiency

Brief summary

This is a validation study of a near-infrared spectroscopy (NIRS) device designed to measure the cerebral tissue oxygen saturation.

Interventions

The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.

Sponsors

Medtronic - MITG
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 46 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy, male or female subjects between the ages of 18 to ≤46 years; 2. Completion of a health screening for a medical history by a licensed physician, nurse practitioner or physician assistant; 3. Minimum weight 40kg; 4. BMI within range 18.0 - 30.0.

Exclusion criteria

1. Prior or known allergies to lidocaine (or similar pharmacologic agents, e.g., Novocain) \[self-reported\]; 2. Prior known severe allergies to medical grade adhesive/tape (Band-Aid) \[self-reported\]; 3. Taking any medication other than birth control \[self-reported\]; 4. Is currently participating in, or has recently participated in (discontinued within 30 days prior to the hypoxia procedure for this study) in an investigational drug, device, or biologic study \[self-reported\]; 5. Has a negative Allen's Test to confirm non-patency of the collateral artery \[clinical assessment by PI or delegate\]; 6. Has made a whole blood donation or has had at least 450 ml of blood drawn within 8 weeks prior to the study procedure \[self-reported\]; 7. Is female with a positive pregnancy test \[serum or urine\], or is female and is unwilling to use effective birth control between the time of screening and study procedure or is breastfeeding; 8. Has anemia \[lab values specific for gender\]; 9. Has a history of sickle cell trait or thalassemia \[self-reported\]; 10. Has an abnormal hemoglobin electrophoresis test \[lab measurement\]; 11. Has a positive urine cotinine test or urine drug screen or oral ethanol test \[POC testing\]; 12. Has a room air saturation less than 95% by pulse oximetry \[measurement by PI or delegate\]; 13. Has a clinically significant abnormal ECG \[assessment by PI or delegate\]; 14. Has a clinically significant abnormal pulmonary function test via spirometry \[assessment by PI or delegate\]; 15. Has a COHb greater than 3%, or MetHb greater than 2% \[measured by venous blood sample co-oximetry\]

Design outcomes

Primary

MeasureTime frameDescription
Validated the Next Generation OximeterData collected from individual participant over 4 hour timeframe.Cerebral overall mean bias (percentage saturation) defined as the average of the differences between the regional saturation (rSO2) value and (fSO2) value obtained from simultaneous arterial and jugular venous blood samples. Cerebral trending is defined as the measurement of changes in regional saturation (rSO2) under conditions of changing fSO2. Cerebral trending mean bias is the average difference between changes in rSO2 values compared against changes in fSO2. Somatic trending mean bias is defined the same as Cerebral trending mean bias except for the location of measurement on the subjects and for Somatic trending mean bias, rS02 was compared to rSO2 on a commercially-available regional oximetry monitor. The smaller value the better performance.

Countries

United States

Participant flow

Participants by arm

ArmCount
Desaturation
Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%. Desaturation: The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
32
Total32

Baseline characteristics

CharacteristicDesaturation
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
32 Participants
Age, Continuous31.4 years
STANDARD_DEVIATION 6.66
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
10 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
19 Participants
Region of Enrollment
United States
32 Participants
Sex: Female, Male
Female
15 Participants
Sex: Female, Male
Male
17 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 32
other
Total, other adverse events
2 / 32
serious
Total, serious adverse events
0 / 32

Outcome results

Primary

Validated the Next Generation Oximeter

Cerebral overall mean bias (percentage saturation) defined as the average of the differences between the regional saturation (rSO2) value and (fSO2) value obtained from simultaneous arterial and jugular venous blood samples. Cerebral trending is defined as the measurement of changes in regional saturation (rSO2) under conditions of changing fSO2. Cerebral trending mean bias is the average difference between changes in rSO2 values compared against changes in fSO2. Somatic trending mean bias is defined the same as Cerebral trending mean bias except for the location of measurement on the subjects and for Somatic trending mean bias, rS02 was compared to rSO2 on a commercially-available regional oximetry monitor. The smaller value the better performance.

Time frame: Data collected from individual participant over 4 hour timeframe.

ArmMeasureGroupValue (MEAN)Dispersion
DesaturationValidated the Next Generation OximeterCerebral Overall Mean Bias1.22 Percentage saturationStandard Deviation 5.92
DesaturationValidated the Next Generation OximeterCerebral Overall Trending Mean Bias0.83 Percentage saturationStandard Deviation 3.08
DesaturationValidated the Next Generation OximeterSomatic Overall Trending Mean Bias0.09 Percentage saturationStandard Deviation 1.73

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026